Answers are grounded in this paper and cite their sources.
Refractory diabetic macular edema (DME) is challenging in resource-limited settings, where costly alternatives such as non-bevacizumab anti-vascular endothelial growth factors (VEGFs) and corticosteroid implants are inaccessible. In Thailand, budget constraints exclude these drugs from healthcare schemes covering 92% of the population, a common issue in developing Asian countries. Therefore, this study aimed to evaluate the treatment outcome of repeated intravitreal triamcinolone acetonide (IVTA) dosages for DME refractory to intravitreal bevacizumab over a 12-month period using a decision algorithm. This was a comparative retrospective study. The included patients were randomly divided into two groups that received either 2 mg or 4 mg IVTA, following a decision algorithm. The primary outcome was the difference in central macular thickness (CMT) between the 2 mg IVTA and 4 mg IVTA groups at 6-month and 12-month follow-up visits. Overall, 81 eyes (62 patients) with DME refractory to bevacizumab were enrolled. The study involved 53 eyes (37 cases) divided into two groups: group 1 (2 mg IVTA) of 14 eyes, and group 2 (4 mg IVTA) of 39 eyes. The 4 mg IVTA group had a higher initial CMT than their 2 mg IVTA counterparts (P = 0.02). This difference disappeared after 6 and 12 months. The improvement in CMT in both groups was maintained across the 6- and 12-month follow-up periods compared with baseline. Univariate logistic regression analysis revealed that patients with thinner CMT before IVTA treatment had a greater probability of being DME-free over long-term follow-up. Repeated IVTA treatments for DME refractory to bevacizumab over a 12-month period demonstrated efficacy and appeared to have a comparable safety profile. Patients with thinner CMT before IVTA treatment had a greater probability of remaining DME-free after IVTA treatment. Treating refractory diabetic macular edema (DME) is challenging in countries with limited resources. Expensive treatments such as non-bevacizumab anti-VEGFs and corticosteroid implants are often unavailable to many patients. In Thailand, where 92% of the population relies on government healthcare, these costly alternatives are not covered. This issue is common in many developing Asian countries. Intravitreal triamcinolone acetonide (IVTA) is a proven, cost-effective second-line treatment for DME. This study examined whether repeated IVTA injections could help patients whose DME did not improve with bevacizumab. Researchers followed patients for 12 months using a treatment plan based on a decision algorithm. This study reviewed past cases of patients with refractory DME. Researchers randomly divided the patients into two groups: one received a 2 mg dose of IVTA, while the other received 4 mg. The goal was to compare changes in central macular thickness (CMT) between the two groups at 6 and 12 months after treatment. A total of 62 patients (81 eyes) participated in the study. Among them, 37 patients (53 eyes) were divided into two groups: 2 mg IVTA group (14 eyes), and 4 mg IVTA group (39 eyes). At the start of the study, the 4 mg group had thicker macula than the 2 mg group (P = 0.02). This difference disappeared after 6 and 12 months. Both groups showed sustained improvement in CMT at 6 and 12 months compared with baseline. Further analysis revealed that patients with thinner CMT before IVTA treatment were more likely to remain DME-free in the long term. Repeated IVTA injections over 12 months were effective for treating DME that did not respond to bevacizumab. Both doses appeared to have a similar safety profile. Patients who started with thinner CMT were more likely to remain DME-free after treatment.
No takes yet. Share an insight, caveat, or question.
Silpa‐archa et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: